Treatment of hypoxic ovarian cancer cells with the STAT3 inhibitor, HO-3867, led to rapid decreases in STAT3 phosphorylation and supports the use of novel and specific STAT3 inhibitors as an attractive and viable therapeutic option in conjunction with HGFL/Ron inhibition for prostate cancer patients [30]. This evidence concerns the gene MST1 and Familial prostate cancer.